Previous studies have demonstrated that EpCAM knockdown results in increased sensitivity to chemotherapy and radiotherapy in prostate cancer cells, which is interpreted by inactivation of PI3K/AKT/mTOR signaling [58]. The gene discussed is EPCAM; the disease is prostate cancer.